Moderna, Inc. (MRNA) is a biotechnology firm based in Cambridge, Massachusetts, that focuses on mRNA technology to create ...

In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

IBM and Moderna have achieved a groundbreaking milestone by simulating the longest mRNA pattern without the use of AI, instead leveraging the power of quantum computing. This collaboration marks a ...

Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...

Telemark Asset Management, LLC established a new position in Moderna ( MRNA +6.66%), acquiring 500,000 shares valued at approximately $12.91 million as of September 30, 2025, according to a November ...

CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...

NEW YORK -- When the final Phase 3 data came out last November showing the mRNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective, Dr. Anthony Fauci had no words. He texted ...

Moderna Inc became the second U.S company to release data from a large study of its experimental vaccine, saying it was 94.5% effective against COVID-19.

Moderna says the first doses have been administered in a trial of an HIV vaccine that uses mRNA technology, which is also used in its COVID-19 vaccine. "We believe that mRNA offers a unique ...

Moderna became a household name during the pandemic because of its leading-edge technology. Investors, as is often the case, extended a positive trend too far into the future. The company's story ...